Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
BOSTON - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported fourth-quarter revenue that exceeded analyst estimates, driving its stock up 0.8% in after-hours trading Monday. The biotechnology company also provided strong full-year 2025 guidance, signaling continued growth expectations.
For the fourth quarter ended December 31, 2024, Vertex posted revenue of $2.91 billion, surpassing the consensus estimate of $2.79 billion. This represents a 16% increase compared to the same quarter last year, primarily driven by the continued strong performance of its cystic fibrosis drug TRIKAFTA/KAFTRIO.
The company reported adjusted earnings per share of $3.98, slightly below the analyst estimate of $4.02. While earnings fell short of expectations, investors appeared to focus more on the revenue beat and positive outlook.
Looking ahead, Vertex provided full-year 2025 revenue guidance of $11.75 billion to $12.0 billion, compared to the consensus estimate of $11.85 billion. This outlook suggests continued strong growth for the company’s product portfolio.
"2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. She highlighted recent approvals and launches, including JOURNAVX for moderate-to-severe acute pain and ALYFTREK for cystic fibrosis.
The company’s cystic fibrosis franchise remains a key driver, with TRIKAFTA/KAFTRIO revenue reaching $2.72 billion in the fourth quarter, up from $2.33 billion in the same period last year.
Vertex also noted progress in its pipeline, including the ongoing launch of CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, as well as multiple ongoing pivotal trials in other disease areas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.